This assay included profiling of antigens (CD123, TIM-3, CD33, CD47, CD90, CD38, CD25, CD70 and U5 snRNP200) being actively assessed in clinical trials10–12 or previously described as putative AML-associated antigens13–15. Here, CD33 is linked to acute myeloid leukemia.